The compassionate communities connectors program: effect on healthcare usage.

chronic disease compassionate communities connectors cost-effectiveness analysis end-of-life care evaluation healthcare usage palliative care social and practical needs social connectedness volunteers

Journal

Palliative care and social practice
ISSN: 2632-3524
Titre abrégé: Palliat Care Soc Pract
Pays: United States
ID NLM: 101754997

Informations de publication

Date de publication:
2023
Historique:
received: 22 06 2023
accepted: 15 09 2023
medline: 30 10 2023
pubmed: 30 10 2023
entrez: 30 10 2023
Statut: epublish

Résumé

Public health approaches to palliative and end-of-life care focus on enhancing the integration of services and providing a comprehensive approach that engages the assets of local communities. However, few studies have evaluated the relative costs and benefits of providing care using these service models. To assess the effect on healthcare usage of a community-based palliative care program ('Compassionate Communities Connectors') where practical and social support was delivered by community volunteers to people living with advanced life-limiting illnesses in regional Western Australia. Controlled before-and-after study/Cost-consequence analysis. A total of 43 community-based patients participated in the program during the period 2020-2022. A comparator population of 172 individuals with advanced life-limiting illnesses was randomly selected from usage data from the same set of health services. Relative to controls, the intervention group had lower hospitalizations per month [Incidence rate ratio (IRR): 0.37; 95% CI: 0.18-0.77, This combined healthcare usage and economic analysis of the 'Compassionate Communities Connectors' program demonstrates the benefits of optimizing palliative care services using home-based and community-centered interventions, with gains for the health system through improved patient outcomes and reduced total healthcare costs (including fewer hospitalizations and readmissions). These findings, coupled with the other published results, suggest that investment in the Connectors program has the capacity to reduce net health sector expenditure while also improving outcomes for people with life-limiting illnesses. Australian and New Zealand Clinical Trial Registry: ACTRN12620000326998.

Sections du résumé

Background UNASSIGNED
Public health approaches to palliative and end-of-life care focus on enhancing the integration of services and providing a comprehensive approach that engages the assets of local communities. However, few studies have evaluated the relative costs and benefits of providing care using these service models.
Objectives UNASSIGNED
To assess the effect on healthcare usage of a community-based palliative care program ('Compassionate Communities Connectors') where practical and social support was delivered by community volunteers to people living with advanced life-limiting illnesses in regional Western Australia.
Design UNASSIGNED
Controlled before-and-after study/Cost-consequence analysis.
Methods UNASSIGNED
A total of 43 community-based patients participated in the program during the period 2020-2022. A comparator population of 172 individuals with advanced life-limiting illnesses was randomly selected from usage data from the same set of health services.
Results UNASSIGNED
Relative to controls, the intervention group had lower hospitalizations per month [Incidence rate ratio (IRR): 0.37; 95% CI: 0.18-0.77,
Conclusion UNASSIGNED
This combined healthcare usage and economic analysis of the 'Compassionate Communities Connectors' program demonstrates the benefits of optimizing palliative care services using home-based and community-centered interventions, with gains for the health system through improved patient outcomes and reduced total healthcare costs (including fewer hospitalizations and readmissions). These findings, coupled with the other published results, suggest that investment in the Connectors program has the capacity to reduce net health sector expenditure while also improving outcomes for people with life-limiting illnesses.
Trial Registration UNASSIGNED
Australian and New Zealand Clinical Trial Registry: ACTRN12620000326998.

Identifiants

pubmed: 37901153
doi: 10.1177/26323524231205323
pii: 10.1177_26323524231205323
pmc: PMC10612440
doi:

Types de publication

Journal Article

Langues

eng

Pagination

26323524231205323

Informations de copyright

© The Author(s), 2023.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest. Ethical approval precludes the data being used for another purpose or being provided to researchers who have not signed the appropriate confidentiality agreement. Specifically, the ethical approval specifies that all results are in aggregate form to maintain confidentiality and privacy and precludes individual level data being made publicly available. All aggregate data for this study are freely available and included in the paper. Interested and qualified researchers may send requests for additional data to Samar Aoun at samar.aoun@perron.uwa.edu.au

Références

Palliat Care Soc Pract. 2023 May 12;17:26323524231173705
pubmed: 37197223
Palliat Med. 2017 Apr;31(4):291-292
pubmed: 28281407
BMC Palliat Care. 2022 Jul 20;21(1):131
pubmed: 35854292
Eur J Intern Med. 2017 Jul;42:39-50
pubmed: 28502866
Healthcare (Basel). 2021 Nov 23;9(12):
pubmed: 34946341
Int J Qual Health Care. 2016 Sep;28(4):456-69
pubmed: 27353273
Br J Gen Pract. 2018 Nov;68(676):e803-e810
pubmed: 30297434
Palliat Care Soc Pract. 2022 Nov 30;16:26323524221139655
pubmed: 36478890
Palliat Med. 2017 Apr;31(4):296-305
pubmed: 28156188
Palliat Med. 2022 Apr;36(4):625-651
pubmed: 35287517
BMC Public Health. 2021 Dec 11;21(1):2253
pubmed: 34895200
BMC Palliat Care. 2018 Mar 7;17(1):42
pubmed: 29514639
Palliat Care Soc Pract. 2022 Nov 30;16:26323524221139874
pubmed: 36466759
Ann Palliat Med. 2018 Apr;7(Suppl 2):S73-S83
pubmed: 29764174
Palliat Care Soc Pract. 2023 Aug 28;17:26323524231193040
pubmed: 37654733
Palliat Med. 2023 Feb;37(2):291-301
pubmed: 36576313

Auteurs

Samar M Aoun (SM)

School of Medicine, Perron Institute for Neurological and Translational Science, The University of Western Australia, 8 Verdun St, Perth WA 6009, Australia.

Natasha Bear (N)

Institute of Health Research, University of Notre Dame Australia, Fremantle, WA, Australia.

Bruce Rumbold (B)

La Trobe University, Melbourne, VIC, Australia Perron Institute for Neurological and Translational Science, Perth, WA, Australia.

Classifications MeSH